The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management
|
|---|---|
| Published in |
Frontiers in Medicine, August 2017
|
| DOI | 10.3389/fmed.2017.00123 |
| Pubmed ID | |
| Authors |
Justin M. Oldham, Harold R. Collard |
| Abstract |
Idiopathic pulmonary fibrosis (IPF), a fibrosing interstitial pneumonia of unknown etiology, primarily affects older adults and leads to a progressive decline in lung function and quality of life. With a median survival of 3-5 years, IPF is the most common and deadly of the idiopathic interstitial pneumonias. Despite the poor survivorship, there exists substantial variation in disease progression, making accurate prognostication difficult. Lung transplantation remains the sole curative intervention in IPF, but two anti-fibrotic therapies were recently shown to slow pulmonary function decline and are now approved for the treatment of IPF in many countries around the world. While the approval of these therapies represents an important first step in combatting of this devastating disease, a comprehensive approach to diagnosing and treating patients with IPF remains critically important. Included in this comprehensive assessment is the recognition and appropriate management of comorbid conditions. Though IPF is characterized by single organ involvement, many comorbid conditions occur within other organ systems. Common cardiovascular processes include coronary artery disease and pulmonary hypertension (PH), while gastroesophageal reflux and hiatal hernia are the most commonly encountered gastrointestinal disorders. Hematologic abnormalities appear to place patients with IPF at increased risk of venous thromboembolism, while diabetes mellitus (DM) and hypothyroidism are prevalent metabolic disorders. Several pulmonary comorbidities have also been linked to IPF, and include emphysema, lung cancer, and obstructive sleep apnea. While the treatment of some comorbid conditions, such as CAD, DM, and hypothyroidism is recommended irrespective of IPF, the benefit of treating others, such as gastroesophageal reflux and PH, remains unclear. In this review, we highlight common comorbid conditions encountered in IPF, discuss disease-specific diagnostic modalities, and review the current state of treatment data for several key comorbidities. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Turkey | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Science communicators (journalists, bloggers, editors) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 109 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 109 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 13% |
| Student > Bachelor | 10 | 9% |
| Student > Ph. D. Student | 8 | 7% |
| Student > Master | 8 | 7% |
| Student > Doctoral Student | 7 | 6% |
| Other | 24 | 22% |
| Unknown | 38 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 38% |
| Nursing and Health Professions | 7 | 6% |
| Biochemistry, Genetics and Molecular Biology | 5 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Psychology | 3 | 3% |
| Other | 5 | 5% |
| Unknown | 44 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 November 2017.
All research outputs
#3,071,932
of 22,996,001 outputs
Outputs from Frontiers in Medicine
#736
of 5,762 outputs
Outputs of similar age
#58,348
of 317,618 outputs
Outputs of similar age from Frontiers in Medicine
#10
of 65 outputs
Altmetric has tracked 22,996,001 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,762 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.2. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,618 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.